It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aspirin is a widely used anti-inflammatory and antithrombotic drug also known in recent years for its promising chemopreventive antineoplastic properties, thought to be mediated in part by its ability to induce apoptotic cell death. However, the full range of mechanisms underlying aspirin’s cancer-preventive properties is still elusive. In this study, we observed that aspirin impaired both the synthesis and transport of acetyl-coenzyme A (acetyl-CoA) into the mitochondria of manganese superoxide dismutase (MnSOD)-deficient Saccharomyces cerevisiae EG110 yeast cells, but not of the wild-type cells, grown aerobically in ethanol medium. This occurred at both the gene level, as indicated by microarray and qRT-PCR analyses, and at the protein level as indicated by enzyme assays. These results show that in redox-compromised MnSOD-deficient yeast cells, but not in wild-type cells, aspirin starves the mitochondria of acetyl-CoA and likely causes energy failure linked to mitochondrial damage, resulting in cell death. Since acetyl-CoA is one of the least-studied targets of aspirin in terms of the latter’s propensity to prevent cancer, this work may provide further mechanistic insight into aspirin’s chemopreventive behavior with respect to early stage cancer cells, which tend to have downregulated MnSOD and are also redox-compromised.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of Malta, Centre for Molecular Medicine and Biobanking, Msida, Malta (GRID:grid.4462.4) (ISNI:0000 0001 2176 9482); University of Malta, Department of Physiology & Biochemistry, Msida, Malta (GRID:grid.4462.4) (ISNI:0000 0001 2176 9482)
2 University of Malta, Centre for Molecular Medicine and Biobanking, Msida, Malta (GRID:grid.4462.4) (ISNI:0000 0001 2176 9482)
3 University of Malta, Department of Pathology, Msida, Malta (GRID:grid.4462.4) (ISNI:0000 0001 2176 9482)
4 NAWI Graz, University of Graz, Institute of Molecular Biosciences, Graz, Austria (GRID:grid.5110.5) (ISNI:0000000121539003)
5 European Molecular Biology Laboratory, Genomics Core Facility, Heidelberg, Germany (GRID:grid.4709.a) (ISNI:0000 0004 0495 846X)
6 University of Malta, Department of Physiology & Biochemistry, Msida, Malta (GRID:grid.4462.4) (ISNI:0000 0001 2176 9482)
7 University of Malta, Department of Applied Biomedical Science, Msida, Malta (GRID:grid.4462.4) (ISNI:0000 0001 2176 9482)
8 NAWI Graz, University of Graz, Institute of Molecular Biosciences, Graz, Austria (GRID:grid.5110.5) (ISNI:0000000121539003); BioTechMed Graz, Graz, Austria (GRID:grid.452216.6)
9 NAWI Graz, University of Graz, Institute of Molecular Biosciences, Graz, Austria (GRID:grid.5110.5) (ISNI:0000000121539003); BioTechMed Graz, Graz, Austria (GRID:grid.452216.6); Central Lab Gracia, NAWI Graz, University of Graz, Graz, Austria (GRID:grid.5110.5) (ISNI:0000000121539003)